1-(2-chloro-4-(2,2,2-trifluoroethoxy)phenyl)ethanone | 1341188-84-8

• 英文名称: 1-(2-chloro-4-(2,2,2-trifluoroethoxy)phenyl)ethanone
• 英文别名: 1-[2-chloro-4-(2,2,2-trifluoroethoxy)phenyl]ethanone
• CAS: 1341188-84-8
• 化学式: C₁₀H₈ClF₃O₂
• 分子量: 252.621
• InChiKey: ULVBQCNEUDIGPV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-(2-chloro-4-(2,2,2-trifluoroethoxy)phenyl)ethanone 、 (R)-(+)-叔丁基亚磺酰胺 、 生成 (R)-N-(1-(2-chloro-4-(2,2,2-trifluoroethoxy)phenyl)ethyl)-2-methylpropane-2-sulfinamide
  参考文献：
  名称：

  ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS

  摘要：

  本发明涉及一种芳基酰胺衍生物，其具有阻断电压门控钠通道（如TTX-S通道）的活性，并且在涉及电压门控钠通道的疾病和疾病的治疗或预防中有用。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在涉及电压门控钠通道的这种疾病的预防或治疗中的使用。

  公开号：

  US20140336377A1

文献信息

• [EN] PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS<br/>[FR] DÉRIVÉS DE PYRROLOPYRIDINONE EN TANT QUE BLOQUANTS DES TTX-S
  申请人：RAQUALIA PHARMA INC

  公开号：WO2013161312A1

  公开（公告）日：2013-10-31

  The present invention relates to pyrrolopyridinone derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.

  本发明涉及吡咯并吡啶酮衍生物，这些衍生物对TTX-S型电压门控钠通道具有阻断作用，并且在治疗或预防涉及电压门控钠通道的疾病和障碍中具有用途。发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在预防或治疗涉及电压门控钠通道的疾病中的使用。
• UREA DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE OF THESE
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：EP1867639A1

  公开（公告）日：2007-12-19

  Urea derivatives represented by the following general formula (I) : which have an agonism of V2 receptor, are useful as agents for the treatment or prevention of diabetes insipidus, nocturia, nocturnal enuresis, overactive bladder or the like. In the formula, R1 represents a hydrogen atom or a C1-6 alkyl group which may have a substituent, R2 is a hydrogen atom or a C1-6 alkyl group, R3 is a hydrogen atom, a C1-6 alkyl group or the like, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, R7 is a hydrogen atom, a heteroaryl group which may have a substituent, a C3-8 cycloalkyl group, an amino group which may have a substituent or a C1-6 alkoxy group which may have a substituted group, M1 is a single bond, a C1-4 alkylene group or the like, Y is N or CRF (in the formula, and RF represents a hydrogen atom, a C1-6 alkyl group or the like, or pharmaceutically acceptable salts thereof, or prodrugs thereof, or pharmaceutical compositions comprising the same and pharmaceutical uses thereof.

  以下一般公式（I）所代表的尿素衍生物，具有V2受体的激动作用，可用作治疗或预防尿崩症、夜尿、夜间遗尿、膀胱过度活动等药物。在公式中，R1代表氢原子或可能具有取代基团的C1-6烷基；R2是氢原子或C1-6烷基；R3是氢原子、C1-6烷基或其他基团；R4、R5和R6独立地是氢原子、卤素原子或其他基团；R7是氢原子、可能具有取代基团的杂环烷基、C3-8环烷基、可能具有取代基团的氨基或可能具有取代基团的C1-6烷氧基；M1是单键、C1-4烷基或其他基团；Y是N或CRF（在公式中，RF代表氢原子、C1-6烷基或其他基团），或其药学上可接受的盐、前药、包含相同成分的药物组合物及其药用。
• [EN] ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS<br/>[FR] DÉRIVÉS D'ARYLAMIDE EN TANT QU'AGENTS BLOQUANTS DE TTX-S
  申请人：RAQUALIA PHARMA INC

  公开号：WO2012053186A1

  公开（公告）日：2012-04-26

  The present invention relates to arylamide derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.

  本发明涉及具有对电压门控钠通道（如TTX-S通道）具有阻塞活性的芳基酰胺衍生物，用于治疗或预防涉及电压门控钠通道的疾病和疾病。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗涉及电压门控钠通道的这类疾病中使用这些化合物和组合物。
• PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS
  申请人：RaQualia Pharma Inc.

  公开号：US20150094306A1

  公开（公告）日：2015-04-02

  The present invention relates to pyrrolopyridinone derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.

  本发明涉及吡咯吡啶酮衍生物，其具有阻断电压门控钠通道（如TTX-S通道）的活性，并且在治疗或预防涉及电压门控钠通道的疾病和疾病方面非常有用。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗涉及电压门控钠通道的疾病方面使用这些化合物和组合物。
• Pyrrolopyridinone derivatives as TTX-S blockers
  申请人：RaQualia Pharma Inc.

  公开号：US09187475B2

  公开（公告）日：2015-11-17

  The present invention relates to pyrrolopyridinone derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.

  本发明涉及一种具有阻断电压门控钠通道（TTX-S通道）活性的吡咯吡啶酮衍生物，其可用于治疗或预防涉及电压门控钠通道的疾病和疾病。本发明还涉及包含这些化合物的制药组合物以及在涉及电压门控钠通道的这些疾病的预防或治疗中使用这些化合物和组合物的用途。